<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02364635</url>
  </required_header>
  <id_info>
    <org_study_id>CTN401614104</org_study_id>
    <nct_id>NCT02364635</nct_id>
  </id_info>
  <brief_title>Icosabutate - A Phase I, Single Oral Dose, Safety, Tolerability and Pharmacokinetic Study in Healthy Subjects</brief_title>
  <official_title>PRC 4016 (Icosabutate) - A Phase I, Single-Blind, Placebo Controlled, Single Oral Dose, Safety, Tolerability and Pharmacokinetic Study in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pronova BioPharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pronova BioPharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      PRC 4016 (Icosabutate) - A Phase I, Single-Blind, Placebo Controlled, Single Oral Dose,
      Safety, Tolerability and Pharmacokinetic Study in Healthy Subjects

      Objective:

        -  To assess the safety and tolerability of single ascending oral doses of icosabutate in
           healthy subjects

        -  To evaluate the pharmacokinetic (PK) parameters of icosabutate in healthy subjects
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic assessments of icosabutate - AUC</measure>
    <time_frame>0-36 hour</time_frame>
    <description>Exposure level of icosabutate measured as Area Under the Curve (AUC)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic assessments of icosabutate - Cmax</measure>
    <time_frame>0-36 hour</time_frame>
    <description>Maximum observed plasma concentration of icosabutate (Cmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with Adverse Events</measure>
    <time_frame>During the 36 hour assessment, and at post-study visit day 5-7</time_frame>
    <description>Clinically significant abnormalities found during the course of the study will be followed up until they return to normal or can be clinically explained</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Icosabutate dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Icosabutate dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Icosabutate dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (medium chain triglycerides)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Icosabutate dose 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 4</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>icosabutate</intervention_name>
    <description>Single dose at each dose levet</description>
    <arm_group_label>Icosabutate dose 1</arm_group_label>
    <arm_group_label>Icosabutate dose 2</arm_group_label>
    <arm_group_label>Icosabutate dose 3</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Icosabutate dose 4</arm_group_label>
    <other_name>PRC-4016</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  males of females

          -  any ethnic origin

          -  Age 18-55 years

          -  BMI 18.0 - 33.0 kg/m2

          -  generally in good health

          -  signed informed consent

        Exclusion Criteria:

          -  males or females not willing to use appropriate contraception

          -  recent blood donation

          -  recent blood received

          -  high consumption of alcohol

          -  high consumption of tobacco

          -  subjects who have engaged in heavy exercise last two weeks

          -  prescribed systemic or topical medication taken recently, or supplements/remedies
             interfering with study procedures or safety

          -  other medication know to alter drug absorption or elimination

          -  abnormal heart rate or blood pressure or 12-lead ECG

          -  significant history of drug allergy, or hypersensitivity to treatment ingredients

          -  ocular disorder requiring topical ocular therapy, or recent allergic eye disease

          -  other significant medical history or physical findings
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ashley Brooks, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Covance</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance Clinical Research Unit (CRU) Ltd.</name>
      <address>
        <city>Leeds</city>
        <zip>LS2 9LH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 22, 2015</study_first_submitted>
  <study_first_submitted_qc>February 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 18, 2015</study_first_posted>
  <last_update_submitted>September 28, 2015</last_update_submitted>
  <last_update_submitted_qc>September 28, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 29, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase I pharmacokinetics and safety study</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

